All In Biotech

Drug Trial Radar · NCT01010061

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.

Last checked: Nov 19, 2026Latest source record: Sep 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 787 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

787

Actual

Start

Dec 21, 2009

Primary completion

Jul 1, 2012

Study completion Aug 23, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
German CLL Study Group; Genentech, Inc.
First posted
Nov 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is \>6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.

Conditions

  • Lymphocytic Leukemia, Chronic

Interventions

  • obinutuzumabDrug

    1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).

  • rituximabDrug

    375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.

  • chlorambucilDrug

    Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
  2. Percentage of Participants With Progression Free Survival EventsTime frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

Locations

261 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    San Diego, California

  • Site not named

    Chicago, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Green Bay, Wisconsin

  • Site not named

    Waukesha, Wisconsin

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Rosario, Argentina

  • Site not named

    Adelaide, New South Wales, Australia

  • Site not named

    Gosford, New South Wales, Australia

  • Site not named

    Kogarah, New South Wales, Australia

  • Site not named

    Liverpool, New South Wales, Australia

  • Site not named

    St Leonards, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Greenslopes, Queensland, Australia

  • Site not named

    Southport, Queensland, Australia

  • Site not named

    Woolloongabba, Queensland, Australia

  • Site not named

    Kurralta Park, South Australia, Australia

  • Site not named

    Frankston, Victoria, Australia

  • Site not named

    Melbourne, Victoria, Australia

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Goiânia, Goiás, Brazil

  • Site not named

    Belo Horizonte, Minas Gerais, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    Santo André, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Vratsa, Bulgaria

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Edmonton, Alberta, Canada

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.